Vexplatin-50/Vexplatin-100

In combination w/ infusional 5-fluorouracil/leucovorin for the adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. Treatment of advanced CRC.

Adjuvant therapy in patients w/ stage III colon cancer Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL of 5% (50 mg/mL) glucose soln given at the same time as leucovorin 200 mg/m² IV infusion in 5% glucose soln over 2-6 hr in separate bags using a Y-line. Followed by 5-fluorouracil 400 mg/m² IV bolus given over 2-4 min, followed by 5-fluorouracil 600 mg/m² IV infusion in 500 mL of 5% glucose soln as 22-hr continuous infusion. Day 2: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL of 5% (50 mg/mL) glucose soln given at the same time as leucovorin 200 mg/m² IV infusion in 5% glucose soln over 2-6 hr in separate bags using a Y-line. Followed by 5-fluorouracil 400 mg/m² IV bolus given over 2-4 min, followed by 5-fluorouracil 600 mg/m² IV infusion in 500 mL of 5% glucose soln as 22-hr continuous infusion. Advanced CRC Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL of 5% (50 mg/mL) glucose soln given as the same time as leucovorin 200 mg/m² IV infusion in 5% glucose soln over 2-6 hr in separate bags using a Y-line. Followed by 5-fluorouracil 400 mg/m² IV bolus given over 2-4 min, followed by 5-fluorouracil 600 mg/m² IV infusion in 500 mL of 5% glucose soln as 22-hr continuous infusion. Repeat cycle every 2 wk.

Patients w/ acute, reversible, primarily peripheral, sensory neuropathy that is of early onset, occurring w/in an hr or 1-2 days of dosing that resolves w/in 14 days & that frequently recurs w/ further dosing. Persistent (>14 days), primarily peripheral, sensory neuropathy.

Do not dilute in NaCl soln or Cl containing soln. Acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Risk of low blood cell counts. Do not mix or administer simultaneously through the same line w/ alkaline medications or media (eg, basic soln of 5-fluorouracil). History of hypersensitivity. Myelosuppression prior to starting 1st course (baseline neutrophils <1.5 x 10⁹/L &/or platelet count of <100 x 10⁶/L); peripheral sensitive neuropathy w/ functional impairment prior to 1st course. Pulmonary fibrosis. Hepatotoxicity (increase in transaminases & alkaline phosphatase). Neuropathy (previously unrated & previously treated patients w/ advanced CRC). Severe renal impairment (CrCl <30 mL/min). Pregnancy & lactation. Childn.

Anaemia, leukopenia, granulocytopenia, thrombocytopenia.

May decrease clearance of potentially nephrotoxic compd. May cause degradation of platinum compd w/ Al.

Cytotoxic Chemotherapy

L01XA03 - oxaliplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

Rx